Submit Content
Get the latest delivered to your inbox
Privacy Policy

Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

    Impacting Human Health: Moderna’s 2021 ESG Report  Image

    POSTED 

    06-24-22

    Impacting Human Health: Moderna’s 2021 ESG Report

    In its 2021 ESG Report, Moderna outlines its corporate responsibility strategy and defines five guiding  focus areas for ongoing and future efforts:
    Moderna Launches New Charitable Foundation Image

    POSTED 

    04-04-22

    Moderna Launches New Charitable Foundation

    Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the launch of the Moderna Charitable Foundation to promote public health, access to quality healthcare and educational opportunities, particularly in underserved populatio...
    Moderna logo

    Moderna

    Moderna

    Join today and get the latest delivered to your inbox